Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03535870 · ClinicalTrials.gov registry record · NA
Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)
A NA study, sponsored by West-Ward Pharmaceutical.
- Completed
- Registry status
- NA
- Development phase
- 1,556
- Enrollment target
NCT03535870: Completed NA study, sponsored by West-Ward Pharmaceutical.
NCT03535870 is a NA study that has completed, run by West-Ward Pharmaceutical. The registered enrollment target is 1,556 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03535870, a NA study, has completed, sponsored by West-Ward Pharmaceutical.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,556 participants
- Enrollment target
Study Summary
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma
Primary Outcome
Baseline-adjusted area under the serial FEV1-time curve calculated from time 0 (zero) to 12 hours on the first day of the Treatment Period
Interventions
- DRUG Placebo
- DRUG Fluticasone propionate/salmeterol
- DRUG Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,556 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2019-09-10 |
| Phase | NA |
What the finished NCT03535870 record still lists
NCT03535870 is an interventional study that assigns participants to a tested intervention. Its 1,556 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03535870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03535870 about?
NCT03535870 is a clinical study titled "Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)". A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma
What is the current status of trial NCT03535870?
This trial is currently completed. It is a NA study. The enrollment target is 1,556 participants. The study started on 2018-04-26. Estimated completion is 2019-09-10.
What interventions are being tested in trial NCT03535870?
The interventions under investigation include: Placebo (DRUG), Fluticasone propionate/salmeterol (DRUG), Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT03535870?
This trial is sponsored by West-Ward Pharmaceutical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03535870's enrollment target sits among peer trials
1,556 64th of 2000 higher than 1,937 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06881069 · 1,560 participants · NA
Reach Through Equitable Implementation in Utah
- NCT02650622 · 1,550 participants
Genetic and Metabolic Disease in Children
- NCT03961945 · 1,550 participants · NA
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
- NCT06034080 · 1,566 participants · NA
Interventions to De-implement Unnecessary Antibiotic Prescribing for Children With Ear Infections
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI